Lipocine Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2014. Lipocine is a clinical-stage specialty pharmaceutical company developing oral drug-delivery products, primarily in men’s and women’s health. It had no product-sale revenue and reported operating losses. The comparative quarter is the three months ended March 31, 2013; the merger-related recapitalization means historical financial statements reflect Lipocine Operating before the 2013 merger.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 or comparison |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $3.37 million | $0.65 million |
| General and administrative expense | $1.92 million | $0.71 million |
| Operating loss | $5.29 million | $1.35 million |
| Net loss | $5.27 million | $1.35 million |
| Basic and diluted loss per share | $0.41 | $0.30 |
| Cash used in operating activities | $3.49 million | $0.76 million |
| Cash and cash equivalents | $41.77 million at March 31, 2014 | $45.26 million at December 31, 2013 |
- Operating expenses rose substantially, principally due to increased external contract research and manufacturing costs, mainly for LPCN 1021, and higher personnel, public-company and stock-compensation costs.
- Cash used in investing activities was $1,866; there were no financing activities during the quarter. Cash declined by $3.49 million from year-end.
- Total assets were $42.10 million and total liabilities were $1.50 million at March 31, 2014. The filing reports no debt or credit facility. Current assets were $42.03 million and current liabilities $1.50 million.
- No profit margin is meaningful because the company had no revenue. Accumulated deficit was $53.13 million.
Business developments, outlook and risks
- LPCN 1021: Enrollment in the pivotal Phase 3 SOAR trial was complete. Management expected top-line efficacy results in Q3 2014 and final results in the second half of 2015. The company estimated approximately $17.6 million to complete development activities through an NDA filing, subject to timing, cost and regulatory uncertainties.
- Other candidates: A Phase 2 proof-of-concept study for LPCN 1111 was expected to begin in Q2 2014. LPCN 1107 Phase 1/2 pharmacokinetic study enrollment was complete, with results expected in Q2 2014. The filing highlights that oral hydroxyprogesterone had not previously been administered to humans and that further studies or FDA requirements could affect development.
- Management expected significant expenses and operating losses to continue for at least several years. It said existing capital resources were expected to fund projected operating requirements for the next 12 months, while noting that additional capital would eventually be needed and might not be available on acceptable terms or at all.
- Risks include clinical-trial outcomes and delays, FDA requirements, manufacturing and registration-batch costs, dependence on third parties, and potential dilution or adverse terms if additional financing is raised. The company said it had 13 employees and identified managing growth as a risk.
- Potential Abbott royalties apply if specified legacy formulations or data are used in products or regulatory filings: 1.5% or 1% of net sales, respectively, subject to the disclosed limits and terms. No royalties were incurred in the quarter.
- A May 6, 2014 lease amendment extended the office and laboratory lease through February 2018; remaining minimum payments were approximately $1.15 million. The amendment occurred after quarter-end.
- Lipocine assigned cough-and-cold intellectual property and the Nexgen agreement to related-party Spriaso in 2013. Lipocine is entitled to 20% of Spriaso’s net proceeds up to $10 million and has a license-back for development outside the cough-and-cold field. The company did not consolidate Spriaso.
- Management said disclosure controls were effective at March 31, 2014 and that two material weaknesses in internal control over financial reporting identified at year-end 2013 had been remediated by quarter-end. No material legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether LPCN 1021’s expected trial milestones were achieved, and the actual clinical, regulatory and development-cost outcomes.
- Cash burn and runway against management’s stated funding horizon, including the timing and terms of any subsequent capital raising.
- Whether development timelines and anticipated studies for LPCN 1111 and LPCN 1107 progressed as expected, including any additional FDA requirements.
- The status and effectiveness of the reported remediation of internal-control material weaknesses in later filings.
- Potential financial effects of the Abbott royalty terms, the related-party Spriaso arrangement and the extended lease.